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Abstract
Background: The hospitalization rate for acute coronary syndrome (ACS) for people aged ≤50 has remained stable
over the past decade. Increased serum levels of n-3 polyunsaturated fatty acids (PUFAs), such as eicosapentaenoic
acid (EPA) and docosahexaenoic acid (DHA), are associated with a decreased incidence of cardiovascular events and
mortality in older patients; however, it is currently unknown whether reduced serum levels of n-3 PUFAs is also a
risk factor for ACS in patients aged ≤50 years.
Methods and results: We retrospectively reviewed 102 (male/ female 73/29) Japanese ACS patients whose serum
levels of EPA/arachidonic acid (AA) and DHA/AA were evaluated on admission. The EPA/AA ratio was the lowest
in patients aged ≤50 compared to patients aged 51–74 and ≥75. Pearson correlation analysis showed that early
ACS onset was associated with low EPA/AA and DHA/AA ratios, and multiple regression analysis determined that
decreased ratios of EPA/AA and DHA/AA, and male sex, current smoker status, increased body mass index and
triglyceride levels, independently correlated with early ACS onset. Conversely, low-density and high-density
lipoproteins, glycated hemoglobin, and hypertension did not correlate with early ACS onset. Subgroup analyses of
male patients revealed that decreased ratios of EPA/AA and DHA/AA independently correlated with early ACS onset.
Conclusion: Decreased EPA/AA and DHA/AA ratios may be risk factors for early onset of ACS, suggesting that reduced
EPA/AA and DHA/AA may represent targets for preventing ACS in Japanese young people.
Keywords: Polyunsaturated fatty acids (PUFA), Eicosapentaenoic acid (EPA), Docosahexaenoic acid (DHA), Acute
coronary syndrome (ACS)
Background
In relation to the increased numbers of elderly people,
the rate of young patients with acute coronary syndrome
(ACS), including acute myocardial infarction (AMI), in
Japan has been relatively decreasing; however, the age-
adjusted incidence of AMI over the last 30 years has
conversely been increasing, especially in men [1]. In
addition, the clinical features and outcomes of ACS in
young subjects (≤45 years) are considered to differ from
those in non-young subjects (>45 years), owing to differ-
ences in the lifestyle and diet patterns [2]. Therefore,
identification of new life-style related risk factors for
ACS is important, especially in young subjects. It has
been reported that reduced serum levels of n-3 polyun-
saturated fatty acids (PUFAs), including eicosapenta-
enoic acid (EPA) and docosahexaenoic acid (DHA), are
associated with an increased incidence of cardiovascular
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events and mortality [3, 4]. Additionally, a decreased ra-
tio of serum EPA/arachidonic acid (AA) has been dem-
onstrated to significantly correlate with the onset of
ACS [5], and the serum EPA/AA ratio has been shown
to stepwise increase with age [6], suggesting that re-
duced serum levels of n-3 PUFAs may represent a risk
factor for ACS, especially in young subjects. However, it
is currently unknown whether reduced serum levels of
n-3 PUFAs is a risk factor for early onset ACS, and, ac-
cordingly, this study aimed to investigate this issue.
Material and methods
Patients and study design
We retrospectively reviewed 102 consecutive Japanese
patients diagnosed with ACS who underwent emergent
percutaneous coronary intervention in the Department
of Cardiovascular Medicine at Tokushima University
Hospital between January 2009 and June 2014. The pa-
tients were stratified into 3 groups according to age
(≤50, 51–74, and ≥75 years) and analyzed.
Because all patients aged ≤50 were male, we moreover
performed subgroup analyses after excluding all female
patients, resulting in a total of 73 male patients out
of the total 102 ACS patients being included in the
analyses.
ACS included AMI and unstable angina. AMI was de-
fined as a transient increase of the MB fraction of creat-
ine kinase to a threshold of 3 times the 99th percentile
of the upper reference limit (150 U/ L) after percutan-
eous coronary intervention in patients with ischemic
symptoms and/or typical electrocardiographic findings
(ST elevation) [7]. Unstable angina was defined as an-
gina at rest, accelerated exertional angina combined with
typical electrocardiographic changes (ST depression), or
an increase in the intensity of anti-ischemic therapy
with a transient increase of the MB fraction of creatine
kinase to a threshold of less than 3 times the 99th per-
centile of the upper reference limit, as described previ-
ously [5]. The exclusion criteria were as follows: use of
fish oil supplements or n-3 fatty acid-containing drugs.
In addition, patients with symptomatic, active malig-
nant diseases or liver dysfunction (aspartate amino-
transferase levels >100 IU/L, alanine aminotransferase
levels >100 IU/L) were also excluded.
Hypertensive patients were defined as those with a
systolic blood pressure ≥140 mmHg and/or diastolic
blood pressure ≥90 mmHg, and/or individuals receiving
antihypertensive medications. Dyslipidemic patients were
defined as those with a low-density lipoprotein cholesterol
(LDL-C) level ≥140 mg/dL, a triglyceride level ≥150 mg/
dL, a high-density lipoprotein cholesterol (HDL-C)
level <40 mg/dL, or individuals receiving lipid-lowering
medications. Diabetic patients were defined as individ-
uals receiving insulin or oral hypoglycemic agents or
those with a glycated hemoglobin (HbA1c) level ≥6.5 %,
fasting plasma glucose level ≥126 mg/dL, or non-fasting
plasma glucose level ≥200 mg/dL.
Blood samples were drawn before emergent percutan-
eous coronary intervention on admission. The serum
samples were stored at −30 °C until assayed. The serum
PUFAs composition, including the levels of EPA, DHA,
and AA, was measured by gas–liquid chromatography at
a commercially available laboratory (SRL, Tokyo, Japan)
[8, 9]. The intra- and inter-assay coefficients of variation
for the EPA, DHA, and AA measurements were 1.3 and
3.3 %, 1.5 and 2.2 %, and 1.1 and 2.2 %, respectively.
Since n-6 PUFAs, including AA, are considered pro-
inflammatory fatty acids, and since the EPA/AA ratio is
known to be associated with the incidence of cardiac
events, the EPA/AA and DHA/AA ratios were calculated
[5]. In addition, other biochemical parameters, including
LDL-C, HDL-C, triglycerides, and HbA1c, were also
measured. Body mass index was calculated as an index
of obesity. The smoking status of the patient was ob-
tained by interviews.
Written informed consent was not required because of
the retrospective nature of the investigation. This study
protocol was approved by the Tokushima University
Hospital Ethics Committee and was conducted in ac-
cordance with the Declaration of Helsinki.
Statistical analyses
The Shapiro-Wilk test was performed to evaluate whether
or not the parameters were normally distributed. Non-
normally distributed parameters were expressed as me-
dian and quartiles. Categorical parameters are expressed
as numbers and percentages. After stratification according
to age, differences in the clinical characteristics were
determined by one-way ANOVA or Chi-square tests.
Pearson correlation analysis was performed to determine
the association between the age at ACS onset and the
EPA/AA or DHA/AA ratio. Multiple regression analysis
was used to assess the degrees of association among the
variables, with age at ACS onset as the outcome variable.
Age, body mass index, and the triglyceride, HDL-C, LDL-
C, HbA1c, EPA, DHA, AA, EPA/AA, and DHA/AA levels
were natural log transformed for the statistical analyses,
because of their non-normal distributions. All statistical
analyses were performed using JMP 10 software (SAS,
Cary, NC, USA). Statistical significance was defined
as P < 0.05.
Results
Clinical characteristics of subjects
The characteristics of all patients stratified by age are
shown in Table 1. There were significant differences in
the EPA/AA ratios among the groups. In addition, there
were significant differences in the male sex ratio, body
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mass index, and HDL-C levels, prevalence of current
smokers, and prevalence of angiotensin-converting en-
zyme inhibitors/angiotensin II receptor blocker use, but
not in the triglyceride, LDL-C, HbA1c, EPA, DHA, and
AA levels, DHA/AA ratio, prevalence of dyslipidemia,
hypertension, and diabetes mellitus, and the other ad-
ministered drugs. Pearson correlation analysis showed
that the levels of EPA and DHA were positively associ-
ated with the EPA/AA and DHA/AA ratios, respectively,
in all patients (Additional file 1: Figure S1).
Of note, the patients aged 35–50 were all men. There-
fore, we moreover performed subgroup analyses of male
patients stratified by age (Additional file 2: Table S1). A
significant difference was observed for the EPA/AA ra-
tio, but not DHA/AA.
The female patient characteristics stratified by age are
shown (Additional file 2: Table S2).
Correlation between n-3 PUFAs and age at ACS onset
The Pearson correlation analysis showed that age at
ACS onset was positively associated with the EPA/AA
and DHA/AA ratios in all (Fig. 1) and male patients
(Additional file 1: Figure S2).
Furthermore, multiple regression analysis in all pa-
tients revealed that male sex, and body mass index,
prevalence of current smoker, and level of triglycerides
were negative, and levels of EPA/AA or DHA/AA were
positive contributors to the age at ACS onset (Table 2,
Model 1, 2). However, levels of LDL-C, HDL-C, HbA1c,
and prevalence of hypertension were statistically ex-
cluded. Multiple regression analysis in male patients re-
vealed that levels of EPA/AA or DHA/AA were positive
contributors and level of triglycerides was a negative
contributor to the age at ACS onset. However, the body
mass index, levels of LDL-C, HDL-C, and HbA1c,
Table 1 Clinical characteristics of all patients stratified by age
Variables Total 35–50 y 51–74 y ≥75 y P-value
Number of patients 102 11 57 34 –
Male, n (%) 73 (71.6 %) 11 (100 %) 46 (80.7 %) 16 (47.1 %) <0.001
Age (years) 69 (56–77) 42 (38–49) 64 (56–70) 79 (77–84) <0.001
Body mass index (kg/m2) 24 (22–25) 26 (25–29)*,†† 24 (21–26) 22 (20–24) <0.01
Triglycerides (mg/dL) 111 (67–171) 143 (132–194) 110 (63–177) 95 (66–129) 0.09
HDL-C (mg/dL) 45 (39–59) 42 (34–43)* 47 (40–60) 45 (38–60) 0.04
LDL-C (mg/dL) 114 (92–137) 133 (101–185) 113 (90–132) 117 (84–148) 0.09
HbA1c (%) 5.9 (5.6–6.4) 5.8 (5.4–6.7) 6.0 (5.5–6.6) 5.9 (5.6–6.4) 0.53
Fatty acid concentrations
EPA (μg/mL) 43 (29–65) 28 (21–55)*,† 43 (34–65) 46 (30–69) 0.12
DHA (μg/mL) 119 (97–149) 102 (94–140) 118 (97–150) 125 (97–163) 0.36
AA (μg/mL) 165 (141–206) 193 (164–234) 167 (152–203) 143 (126–211) 0.09
EPA/AA 0.25 (0.17–0.37) 0.17 (0.07–0.23)*,† 0.26 (0.18–0.37) 0.29 (0.19–0.42) 0.03
DHA/AA 0.75 (0.59–0.96) 0.70 (0.47–0.89) 0.67 (0.56–0.95) 0.83 (0.70–1.00) 0.05
Complications
Dyslipidemia, n (%) 38 (37 %) 6 (55 %) 22 (39 %) 10 (29 %) 0.31
Hypertension, n (%) 63 (62 %) 5 (45 %) 34 (60 %) 24 (71 %) 0.29
Diabetes mellitus, n (%) 29 (28 %) 2 (18 %) 19 (33 %) 8 (24 %) 0.44
Current smoking, n (%) 44 (43 %) 9 (82 %) 28 (49 %) 7 (21 %) <0.01
Drugs
ACEI/ARB, n (%) 27 (26 %) 1 (9 %) 11 (19 %) 15 (44 %) 0.01
β-blockers, n (%) 10 (10 %) 1 (9 %) 4 (7 %) 5 (15 %) 0.49
Calcium channel blockers, n (%) 27 (26 %) 1 (9 %) 15 (26 %) 11 (32 %) 0.31
Statins, n (%) 15 (15 %) 2 (18 %) 11 (19 %) 2 (6 %) 0.20
Aspirin, n (%) 16 (16 %) 2 (18 %) 8 (14 %) 6 (18 %) 0.28
Unless indicated otherwise, data are presented as median and quartiles
Abbreviations: AA arachidonic acid, ACEI angiotensin converting enzyme inhibitors, ARB angiotensin II receptor blockers, DHA docosahexaenoic acid, EPA
eicosapentaenoic acid, HbA1c glycated hemoglobin, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol
*P <0.05 (vs. age 51–74)
†P <0.05 (vs. age ≥75)
††P <0.01 (vs. age ≥75)
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prevalence of hypertension and current smoker status
were statistically excluded (Additional file 2: Table S3,
Model 1, 2).
Discussion
Herein, we showed that the EPA/AA ratio was the low-
est in early-onset ACS patients and that low levels of
EPA/AA and DHA/AA were independent contributors
of early onset of ACS.
Although patients with CAD typically become symp-
tomatic after age 40, autopsy studies have demonstrated
that coronary atherosclerosis can begins as early as
20 years of age [10–13], and such atherosclerotic
changes in the coronary arteries have also been observed
in Japanese youths, whose incidence and mortality
from CAD are reportedly the lowest in all industrial-
ized countries [14].
Despite recent advances in the identification of risk
factors, the occurrence of CAD has continued to in-
crease worldwide, and despite the decrease in cardiovas-
cular mortality due to statin treatment, two out of three
patients still experience cardiovascular events [15]. In
addition, the AMI hospitalization rate for relatively
young people has remained stable over the past decade
[16–18], which may be largely due to the insufficient
control of the various CAD risk factors [1]. Several risk
factors for early-onset AMI have been reported; classical
risk factors include serum cholesterol levels, systolic
blood pressure, and cigarette smoking [19], while non-
classical risk factors include vasospastic tendencies,
thrombophilic conditions, and a history of Kawasaki dis-
ease [20, 21]. However, there are currently no universal
guidelines on the prevention of CAD in young people, in
part because of insufficient evidence on coronary disease
prevention in adults younger than 40 years [19].
Therefore, sufficient control of classical CAD risk fac-
tors and identification of residual risk factors for
CAD are needed.
It has been reported that reduced serum levels of n-3
PUFA, especially EPA, are associated with an increased
incidence of cardiovascular events and mortality [3–5],
and the JELIS study, a large clinical trial, showed effects
of EPA on reducing cardiovascular events in hypercho-
lesterolemic patients [22]. However, it should be noted
that the levels of EPA (95 μg/mL) and DHA (170 μg/
mL) in the hyperlipidemic patients without ACS enrolled
in the JELIS trial were higher than those in the ACS pa-
tients in our study (EPA, 43 μg/mL; DHA, 119 μg/mL)
[23]. Furthermore, the Japanese National Health and
Nutrition Survey demonstrated that the type of nutrition
Fig. 1 Pearson correlation analyses in all patients between the age at ACS onset and levels of EPA/AA and DHA/AA. AA arachidonic acid, ACS
acute coronary syndrome, DHA docosahexaenoic acid, EPA eicosapentaenoic acid
Table 2 Multiple regression analysis for determinants of the age
of acute coronary syndrome onset
Variables Coefficient 95 % CI P-value
Model 1
Male sex −0.06 −0.10 to −0.02 <0.01
Body mass index −0.27 −0.50 to −0.05 0.02
Hypertension 0.04 −0.001 to 0.07 0.05
Current smoker −0.04 −0.08 to 0.001 0.06
LDL-C −0.04 −0.12 to 0.04 0.28
Triglycerides −0.08 −0.14 to −0.02 0.01
HDL-C 0.01 −0.13 to 0.16 0.85
HbA1c, % 0.20 −0.03 to 0.44 0.09
EPA/AA 0.07 0.01 to 0.13 0.02
Model 2
Male sex −0.06 −0.10 to −0.02 <0.01
Body mass index −0.24 −0.46 to −0.01 0.04
Hypertension 0.03 −0.001 to 0.07 0.05
Current smoker −0.04 −0.08 to 0.01 0.04
LDL-C −0.04 −0.11 to 0.04 0.31
Triglycerides −0.09 −0.15 to −0.03 <0.01
HDL-C 0.05 −0.10 to 0.19 0.53
HbA1c, % 0.18 −0.05 to 0.41 0.12
DHA/AA 0.15 −0.05 to 0.25 <0.01
Model 1, R2 = 0.37; P <0.001
Model 2, R2 = 0.39; P <0.001
Abbreviations: AA arachidonic acid, CI confidence interval, DHA
docosahexaenoic acid; EPA eicosapentaenoic acid, HbA1c glycated
hemoglobin, HDL-C high-density lipoprotein cholesterol, LDL-C low-density
lipoprotein cholesterol
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has changed from Japanese traditional style to western
style; in particular, fish intake has been decreasing,
especially in people aged 30–49 and 40–49 years
(http://www0.nih.go.jp/eiken/english/research/program_
epidemiology.html), suggesting that low levels of n-3
PUFAs could lead to CAD prevention in young people.
In the study, all patients aged 50 or under were men.
It has been well established that male gender is a risk
factor of CAD [24, 25], and previous studies have shown
that men with ACS are more likely to have ruptured pla-
ques, whereas women are more likely to present with
plaque erosion, suggesting that the mechanism of ACS
development in men and women differs [24]. For ex-
ample, it has been speculated that estrogen might con-
tribute to delaying the plaque development, stabilizing
the existing plaques, and preventing plaque rupture in
women [25].
On the other hand, the underlying mechanisms re-
sponsible for the favorable effects of n-3 PUFAs remain
partly unknown. n-3 PUFAs have been demonstrated to
induce stability of vulnerable plaques, which is con-
sidered to contribute to the protection against acute
cardiovascular events, and it has been shown that ad-
ministration of fish oil increased the proportions of
n-3 PUFAs in carotid plaque lipids and increased the
proportions of well-formed fibrous caps, rather than
thin inflamed caps, as compared with a placebo or
sunflower oil [26]. In addition, a recent study showed
that administration of EPA increased the fibrous cap
thickness of coronary atherosclerotic plaques [27].
Moreover, several studies have shown that long-chain
n-3 PUFAs can decrease the expressions of intercellular
adhesion molecule-1 and vascular cell adhesion molecule-
1 on the surface of endothelial cells [28] and monocytes
[29]. Therefore, n-3 PUFA-induced decreases in adhesion
molecule expression on endothelial cells and/or the
monocyte/macrophage itself, might reduce migration of
monocytes/macrophages into the plaque [30, 31]. Further,
chylomicron remnant-like particles enriched in n-3 PUFA
are taken up more slowly by macrophages than those
enriched in saturated or monounsaturated fatty acids,
which might also be involved in attenuation of plaque for-
mation [32], and it has been shown that administration of
n-3 PUFA reduced the matrix metalloproteinase-7, −9 and
−12 expressions [33]. These gene products are proteases
capable of degrading extracellular matrix proteins, conse-
quently leading to plaque rupture [33]. Accordingly, re-
duced expression of matrix metalloproteinases by n-3
PUFAs may also contribute to plaque instability, leading
to suppression of ACS.
Although some meta-analyses and clinical trials have
shown beneficial effects of n-3 PUFAs on cardiovascular
events [22, 34], a previous systematic review conversely
showed no definite effects of n-3 PUFAs on cardiovascular
events [35]. In addition, some theoretical unfavorable ef-
fects have been reported, including one study showing
that intake of dietary PUFAs such as EPA and DHA in-
creased lipid peroxidation, which may in turn enhance
oxidative stress and cancel the preferable effects of n-3
PUFAs [36]. This unfavorable effect of n-3 PUFAs
may explain the inconsistent clinical results and con-
tribute to the finding that the characteristics of pa-
tients who received beneficial effects of PUFAs differ
among studies [37, 38].
The present study had several limitations. This was
a retrospective study—with a relatively small sample
size—that was performed in a single-center located in
a costal provincial city. Larger clinical cohort studies
are needed to confirm our results and to clarify the
effects of n-3 PUFAs on early-onset ACS.
Conclusions
We here demonstrated that decreased EPA/AA and
DHA/AA ratios may be risk factors for early onset of
ACS, suggesting that reduced EPA/AA and DHA/AA
may represent targets for preventing ACS in Japanese
young people.
Additional files
Additional file 1: Figure S1. Pearson correlation analysis showed that
the levels EPA and DHA were positively associated with the EPA/AA and
DHA/AA ratios, respectively, in all patients. AA, arachidonic acid; DHA,
docosahexaenoic acid; EPA, eicosapentaenoic acid. Figure S2. Pearson
correlation analyses in male patients between the age at ACS onset and
levels of EPA/AA and DHA/AA. AA, arachidonic acid; ACS, acute coronary
syndrome; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid.
(PPTX 101 kb)
Additional file 2: Table S1. Clinical characteristics of the male patients
stratified by age. Table S2. Clinical characteristics of the female patients
stratified by age. Table S3. Multiple regression analysis for contributors of
the age of acute coronary syndrome onset in male patients. (DOCX 25 kb)
Abbreviations
ACS: acute coronary syndrome; AMI: acute myocardial infarction;
CAD: coronary artery disease; PUFAs: polyunsaturated fatty acids;
EPA: eicosapentaenoic acid; DHA: docosahexaenoic acid; AA: arachidonic
acid; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density
lipoprotein cholesterol; HbA1c: glycated hemoglobin.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SY, KA, DF, AT, MB, TH, SN, TIs, KK, KY, TT, TIw, HY, TS, TW, collected data and
SY analyzed the data and wrote the manuscript. MSh, MA, MSa supervised
the study. All authors read and approved the final manuscript.
Acknowledgements
We thank the staff of the Hospital Information Center of Tokushima
University Hospital for retrieving the patient data from the medical records.
This work was supported in part by JSPS KAKENHI (Grant Numbers 25461131
and 25860605).
Yagi et al. Nutrition Journal  (2015) 14:111 Page 5 of 6
Author details
1Department of Cardiovascular Medicine, Institute of Biomedical Sciences,
Tokushima University Graduate School, 3-18-15 Kuramoto, Tokushima
770-8503, Japan. 2Department of Hematology, Endocrinology and
Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate
School, 3-18-15 Kuramoto, Tokushima 770-8503, Japan. 3Department of
Nutrition and Metabolism, Institute of Biomedical Sciences, Tokushima
University Graduate School, 3-18-15 Kuramoto, Tokushima 770-8503, Japan.
4Department of Cardio-Diabetes Medicine, Institute of Biomedical Sciences,
Tokushima University Graduate School, 3-18-15 Kuramoto, Tokushima
770-8503, Japan. 5Department of Medical Education, Institute of Biomedical
Sciences, Tokushima University Graduate School, 3-18-15 Kuramoto,
Tokushima 770-8503, Japan.
Received: 15 June 2015 Accepted: 12 October 2015
References
1. Takii T, Yasuda S, Takahashi J, Ito K, Shiba N, Shirato K, et al. Trends in acute
myocardial infarction incidence and mortality over 30 years in Japan: report
from the MIYAGI-AMI Registry Study. Circ J. 2010;74:93–100.
2. Jinnouchi H, Sakakura K, Wada H, Kubo N, Sugawara Y, Funayama H, et al.
Clinical features of myocardial infarction in young Japanese patients. Int
Heart J. 2013;54:123–8.
3. Amano T, Matsubara T, Uetani T, Kato M, Kato B, Yoshida T, et al. Impact of
omega-3 polyunsaturated fatty acids on coronary plaque instability: an
integrated backscatter intravascular ultrasound study. Atherosclerosis.
2011;218:110–6.
4. Hara M, Sakata Y, Nakatani D, Suna S, Usami M, Matsumoto S, et al. Low
levels of serum n-3 polyunsaturated fatty acids are associated with worse
heart failure-free survival in patients after acute myocardial infarction. Circ J.
2013;77:153–62.
5. Nishizaki Y, Shimada K, Tani S, Ogawa T, Ando J, Takahashi M, et al.
Significance of imbalance in the ratio of serum n-3 to n-6 polyunsaturated
fatty acids in patients with acute coronary syndrome. Am J Cardiol.
2014;113:441–5.
6. Yanagisawa N, Shimada K, Miyazaki T, Kume A, Kitamura Y, Ichikawa R, et al.
Polyunsaturated fatty acid levels of serum and red blood cells in apparently
healthy Japanese subjects living in an urban area. J Atheroscler Thromb.
2010;17:285–94.
7. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al.
Third universal definition of myocardial infarction. Circulation.
2012;126:2020–35.
8. Yagi S, Aihara KI, Fukuda D, Takashima A, Hara T, Hotchi J, et al. Effects of
docosahexaenoic acid on the endothelial function in patients with coronary
artery disease. J Atheroscler Thromb. 2014.
9. Yagi S, Hara T, Ueno R, Aihara KI, Fukuda D, Takashima A, et al. Serum
concentration of eicosapentaenoic acid is associated with cognitive
function in patients with coronary artery disease. Nutr J. 2014;13:112.
10. McNamara JJ, Molot MA, Stremple JF, Cutting RT. Coronary artery disease in
combat casualties in Vietnam. JAMA. 1971;216:1185–7.
11. Tuzcu EM, Kapadia SR, Tutar E, Ziada KM, Hobbs RE, McCarthy PM, et al.
High prevalence of coronary atherosclerosis in asymptomatic teenagers and
young adults: evidence from intravascular ultrasound. Circulation.
2001;103:2705–10.
12. McGill Jr HC, McMahan CA, Zieske AW, Tracy RE, Malcom GT, Herderick EE,
et al. Association of Coronary Heart Disease Risk Factors with microscopic
qualities of coronary atherosclerosis in youth. Circulation. 2000;102:374–9.
13. Kisanuki A, Asada Y, Sato Y, Marutsuka K, Takeda K, Sumiyoshi A. Coronary
atherosclerosis in youths in Kyushu Island, Japan: histological findings and
stenosis. J Atheroscler Thromb. 2000;6:55–9.
14. Ueshima H, Sekikawa A, Miura K, Turin TC, Takashima N, Kita Y, et al.
Cardiovascular disease and risk factors in Asia a selected review. Circulation.
2008;118:2702–9.
15. Libby P. The forgotten majority: unfinished business in cardiovascular risk
reduction. J Am Coll Cardiol. 2005;46:1225–8.
16. Gupta A, Wang Y, Spertus JA, Geda M, Lorenze N, Nkonde-Price C, et al.
Trends in acute myocardial infarction in young patients and differences by
sex and race, 2001 to 2010. J Am Coll Cardiol. 2014;64:337–45.
17. Rumana N, Kita Y, Turin TC, Murakami Y, Sugihara H, Morita Y, et al. Trend of
increase in the incidence of acute myocardial infarction in a Japanese
population: Takashima AMI Registry, 1990–2001. Am J Epidemiol.
2008;167:1358–64.
18. Kitamura A, Sato S, Kiyama M, Imano H, Iso H, Okada T, et al. Trends in the
incidence of coronary heart disease and stroke and their risk factors in Japan,
1964 to 2003 - The Akita-Osaka study. J Am Coll Cardiol. 2008;52:71–9.
19. Navas-Nacher EL, Colangelo L, Beam C, Greenland P. Risk factors for
coronary heart disease in men 18 to 39 years of age. Ann Intern Med.
2001;134:433–9.
20. Doughty M, Mehta R, Bruckman D, Das S, Karavite D, Tsai T, et al. Acute
myocardial infarction in the young—The University of Michigan experience.
Am Heart J. 2002;143:56–62.
21. Yagi S, Tsuda E, Shimizu W, Kurita T, Seguchi O, Nonogi H, et al. Two adults
requiring implantable defibrillators because of ventricular tachycardia and
left ventricular dysfunction caused by presumed Kawasaki disease. Circ J.
2005;69:870–4.
22. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y,
et al. Effects of eicosapentaenoic acid on major coronary events in
hypercholesterolaemic patients (JELIS): a randomised open-label, blinded
endpoint analysis. Lancet. 2007;369:1090–8.
23. Itakura H, Yokoyama M, Matsuzaki M, Saito Y, Origasa H, Ishikawa Y, et al.
Relationships between plasma fatty acid composition and coronary artery
disease. J Atheroscler Thromb. 2011;18:99–107.
24. Hochman JS, Tamis JE, Thompson TD, Weaver WD, White HD, Van de Werf
F, et al. Sex, clinical presentation, and outcome in patients with acute
coronary syndromes. N Engl J Med. 1999;341:226–32.
25. Burke AP, Farb A, Malcom G, Virmani R. Effect of menopause on plaque
morphologic characteristics in coronary atherosclerosis. Am Heart J.
2001;141:S58–62.
26. Thies F, Garry JMC, Yaqoob P, Rerkasem K, Williams J, Shearman CP, et al.
Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic
plaques: a randomised controlled trial. Lancet. 2003;361:477–85.
27. Yamano T, Kubo T, Shiono Y, Shimamura K, Orii M, Tanimoto T, et al. Impact
of eicosapentaenoic acid treatment on the fibrous cap thickness in patients
with coronary atherosclerotic plaque: an optical coherence tomography
study. J Atheroscler Thromb. 2014.
28. De Caterina R, Cybulsky MI, Clinton SK, Gimbrone Jr MA, Libby P. The
omega-3 fatty acid docosahexaenoate reduces cytokine-induced expression
of proatherogenic and proinflammatory proteins in human endothelial cells.
Arterioscler Thromb. 1994;14:1829–36.
29. Hughes DA, Southon S, Pinder AC. (n-3) Polyunsaturated fatty acids
modulate the expression of functionally associated molecules on human
monocytes in vitro. J Nutr. 1996;126:603–10.
30. Kris-Etherton PM, Harris WS, Appel LJ, American Heart Association. Nutrition
C: Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular
disease. Circulation. 2002;106:2747–57.
31. Calder PC. Long-chain n-3 fatty acids and cardiovascular disease: further
evidence and insights. Nutr Res. 2004;24:761–72.
32. De Pascale C, Avella M, Perona JS, Ruiz-Gutierrez V, Wheeler-Jones CPD,
Botham KM. Fatty acid composition of chylomicron remnant-like particles
influences their uptake and induction of lipid accumulation in
macrophages. FEBS J. 2006;273:5632–40.
33. Cawood AL, Ding R, Napper FL, Young RH, Williams JA, Ward MJA, et al.
Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl
esters is incorporated into advanced atherosclerotic plaques and higher
plaque EPA is associated with decreased plaque inflammation and
increased stability. Atherosclerosis. 2010;212:252–9.
34. Bucher HC, Hengstler P, Schindler C, Meier G. N-3 polyunsaturated fatty
acids in coronary heart disease: a meta-analysis of randomized controlled
trials. Am J Med. 2002;112:298–304.
35. Hooper L, Thompson RL, Harrison RA, Summerbell CD, Ness AR, Moore HJ,
et al. Risks and benefits of omega 3 fats for mortality, cardiovascular disease,
and cancer: systematic review. BMJ. 2006;332:752–60.
36. Allard JP, Kurian R, Aghdassi E, Muggli R, Royall D. Lipid peroxidation during n-
3 fatty acid and vitamin E supplementation in humans. Lipids. 1997;32:535–41.
37. Kromhout D, Yasuda S, Geleijnse JM, Shimokawa H. Fish oil and omega-3
fatty acids in cardiovascular disease: do they really work? Eur Heart J.
2012;33:436–43.
38. Marklund M, Leander K, Vikstrom M, Laguzzi F, Gigante B, Sjogren P, et al.
Polyunsaturated fat intake estimated by circulating biomarkers and risk of
cardiovascular disease and all-cause mortality in a population-based cohort
of 60-year-old men and women. Circulation. 2015;132(7):586–94.
Yagi et al. Nutrition Journal  (2015) 14:111 Page 6 of 6
